Modernizing the Functional Service Provider (FSP) Relationship: Innovations to bring value beyond “Global and Scalable”

[Fill out the form below to register]

Abstract: The Global Clinical Research Organization (CRO) market is expected to grow to $71.7 billion in 2024. Within that growth, Functional Service Provider (FSP) relationships are expected to grow at a CAGR of 5%-6%. Sponsor organizations turn to the FSP model as an outsourcing strategy for multiple reasons. Efficiency, consistency, scalability, global reach, and cost reduction generally top that list. CROs, in turn, have evolved their culture, resourcing, and infrastructure to best suit FSP relationships

Given the increasing reliance on global support models, virtual work teams, and the complexity and increasing amounts of data and advancements in technology – sponsor organizations need more from their FSP partners.   The best-fit partners bring the functional line expertise plus an innovation mindset and tangible methods to identify, and where requested, help organizations to transform their way of operating.

Attendees will learn:

  • How FSP partners can go beyond “Global and Scalable”
  • How to bridge time zones and distance without compromising performance
  • How to create and maintain a culture of alignment with customer goals, standards, and results
  • Innovative methods for leading the charge to bring innovation and efficiencies
  • Sample innovations that have transformed FSP partnership operating models

This webinar is intended for small to mid-size organizations – those utilizing the FSP model today and those considering implementing FSP relationships in the future.

Presenters:

Donnelle LaDouceur, Director, Functional Service Solutions

Jim Balcom, Director, Innovation and Automation

Diederik Van Niekerk, Senior Manager, South Africa Operations

mms holdings fsp functional service provider provision webinar expert solutions services cro pharmaceutical biotech medical device industry biostatistics programming data science medical writing drug safety pharmacovigilance

Register for the webinar

Suggested For You

perspectives

May 13th, 2026

Beyond Data Cleaning: A Strategic Shift for Clinical Data Management under ICH E6 (R3)

perspectives

May 5th, 2026

A Statistician's Reflection: FDA Guidance on Limiting Crossover in Oncology Studies 

perspectives

April 27th, 2026

From Stigma to Signal: The Executive Order, CNPV Vouchers, and What Comes Next for Psychedelics

perspectives

April 20th, 2026

The FDA Drug Shortage List Signals Deeper Concerns for the US Medicine Supply Chain

perspectives

April 15th, 2026

Decision-Making in Early-Phase Oncology Trials: Navigating Uncertainty with Evidence Frameworks

perspectives

April 8th, 2026

Four Pillars of My Success as a Clinical Trial Transparency Specialist

perspectives

March 25th, 2026

REMS and Labeling Are Strategic Design Decisions, Not Late-Stage Add-Ons

perspectives

March 12th, 2026

AI in Pharma: Autopilot Is Not the Same as Removing the Pilot 

perspectives

March 3rd, 2026

Modeling and Simulation in Clinical Trials: A Practical Approach to De-Risking Study Design

perspectives

February 25th, 2026

Integrating AI and Automation Into Clinical Trial Operations With Discipline and Transparency

perspectives

February 10th, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development 

perspectives

February 3rd, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development